secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2025-09-09T23:59:59+00:00
Accession:  0001558370-25-011954
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent reports 16.0-month mPFS with firmonertinib in EGFR PACC NSCLC Phase 1b final analysis
--------------------------------------------------------------------------------

- Median PFS 16.0 months by BICR with firmonertinib 240 mg once daily in first-line EGFR PACC NSCLC.
- Confirmed ORR 68.2% at 240 mg; median DOR 14.6 months by BICR; responses across multiple PACC mutation types.
- CNS confirmed ORR 42.9% (6/14) with 35.7% CNS complete responses by BICR in evaluable patients.
- First patient enrollment in global pivotal Phase 3 ALPACCA trial expected in H2 2025.
- Safety profile maintained; most common TEAEs: diarrhea, hepatic enzyme elevation, rash; no new signals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000155837025011954/0001558370-25-011954-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000155837025011954/avbp-20250909x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011954

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer